PURPOSE: (213)Bi-d9MAb-immunoconjugates targeting gastric cancer cells have effectively cured peritoneal carcinomatosis in a nude mouse model following intraperitoneal injection. Because the β-emitter (177)Lu has proven to be beneficial in targeted therapy, (177)Lu-d9MAb was investigated in this study in order to compare its therapeutic efficacy and toxicity with those of (213)Bi-d9MAb. METHODS: Nude mice were inoculated intraperitoneally with HSC45-M2 gastric cancer cells expressing d9-E-cadherin and were treated intraperitoneally 1 or 8 days later with different activities of specific (177)Lu-d9MAb immunoconjugates targeting d9-E-cadherin or with nonspecific (177)Lu-d8MAb. Therapeutic efficacy was evaluated by monitoring survival for up to 250 days. For evaluation of toxicity, both biodistribution of (177)Lu-d9MAb and blood cell counts were determined at different time points and organs were examined histopathologically. RESULTS: Treatment with (177)Lu-immunoconjugates (1.85, 7.4, 14.8 MBq) significantly prolonged survival. As expected, treatment on day 1 after tumour cell inoculation was more effective than treatment on day 8, and specific (177)Lu-d9MAb conjugates were superior to nonspecific (177)Lu-d8MAb. Treatment with 7.4 MBq of (177)Lu-d9MAb was most successful, with 90% of the animals surviving longer than 250 days. However, treatment with therapeutically effective activities of (177)Lu-d9MAb was not free of toxic side effects. In some animals lymphoblastic lymphoma, proliferative glomerulonephritis and hepatocarcinoma were seen but were not observed after treatment with (213)Bi-d9MAb at comparable therapeutic efficacy. CONCLUSION: The therapeutic efficacy of (177)Lu-d9MAb conjugates in peritoneal carcinomatosis is impaired by toxic side effects. Because previous therapy with (213)Bi-d9MAb revealed comparable therapeutic efficacy without toxicity it should be preferred for the treatment of peritoneal carcinomatosis.
PURPOSE: (213)Bi-d9MAb-immunoconjugates targeting gastric cancer cells have effectively cured peritoneal carcinomatosis in a nude mouse model following intraperitoneal injection. Because the β-emitter (177)Lu has proven to be beneficial in targeted therapy, (177)Lu-d9MAb was investigated in this study in order to compare its therapeutic efficacy and toxicity with those of (213)Bi-d9MAb. METHODS:Nude mice were inoculated intraperitoneally with HSC45-M2 gastric cancer cells expressing d9-E-cadherin and were treated intraperitoneally 1 or 8 days later with different activities of specific (177)Lu-d9MAb immunoconjugates targeting d9-E-cadherin or with nonspecific (177)Lu-d8MAb. Therapeutic efficacy was evaluated by monitoring survival for up to 250 days. For evaluation of toxicity, both biodistribution of (177)Lu-d9MAb and blood cell counts were determined at different time points and organs were examined histopathologically. RESULTS: Treatment with (177)Lu-immunoconjugates (1.85, 7.4, 14.8 MBq) significantly prolonged survival. As expected, treatment on day 1 after tumour cell inoculation was more effective than treatment on day 8, and specific (177)Lu-d9MAb conjugates were superior to nonspecific (177)Lu-d8MAb. Treatment with 7.4 MBq of (177)Lu-d9MAb was most successful, with 90% of the animals surviving longer than 250 days. However, treatment with therapeutically effective activities of (177)Lu-d9MAb was not free of toxic side effects. In some animals lymphoblastic lymphoma, proliferative glomerulonephritis and hepatocarcinoma were seen but were not observed after treatment with (213)Bi-d9MAb at comparable therapeutic efficacy. CONCLUSION: The therapeutic efficacy of (177)Lu-d9MAb conjugates in peritoneal carcinomatosis is impaired by toxic side effects. Because previous therapy with (213)Bi-d9MAb revealed comparable therapeutic efficacy without toxicity it should be preferred for the treatment of peritoneal carcinomatosis.
Authors: Shankar Vallabhajosula; Stanley J Goldsmith; Lale Kostakoglu; Mathew I Milowsky; David M Nanus; Neil H Bander Journal: Clin Cancer Res Date: 2005-10-01 Impact factor: 12.531
Authors: Rosana B Michel; Philip M Andrews; Adriane V Rosario; David M Goldenberg; M Jules Mattes Journal: Nucl Med Biol Date: 2005-04 Impact factor: 2.408
Authors: Manuel J Koppe; Robert P Bleichrodt; Annemieke C Soede; Albert A Verhofstad; David M Goldenberg; Wim J G Oyen; Otto C Boerman Journal: J Nucl Med Date: 2004-07 Impact factor: 10.057
Authors: E J Rolleman; B F Bernard; W A P Breeman; F Forrer; E de Blois; J Hoppin; M Gotthardt; O C Boerman; E P Krenning; M de Jong Journal: Nuklearmedizin Date: 2008 Impact factor: 1.379
Authors: Sandra Heskamp; Reinier Hernandez; Janneke D M Molkenboer-Kuenen; Markus Essler; Frank Bruchertseifer; Alfred Morgenstern; Erik J Steenbergen; Weibo Cai; Christof Seidl; William J McBride; David M Goldenberg; Otto C Boerman Journal: J Nucl Med Date: 2017-02-23 Impact factor: 10.057
Authors: Sofia H L Frost; Shani L Frayo; Brian W Miller; Johnnie J Orozco; Garrett C Booth; Mark D Hylarides; Yukang Lin; Damian J Green; Ajay K Gopal; John M Pagel; Tom A Bäck; Darrell R Fisher; Oliver W Press Journal: PLoS One Date: 2015-03-18 Impact factor: 3.240
Authors: Narges K Tafreshi; Michael L Doligalski; Christopher J Tichacek; Darpan N Pandya; Mikalai M Budzevich; Ghassan El-Haddad; Nikhil I Khushalani; Eduardo G Moros; Mark L McLaughlin; Thaddeus J Wadas; David L Morse Journal: Molecules Date: 2019-11-26 Impact factor: 4.411